Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Orphan Drugs

- PMLiVE

FDA approves sleep disorder drug for blind people

Vanda Pharmaceuticals wins backing for Hetlioz to improve a person’s body clock

- PMLiVE

EU gives boost to its network of HTA bodies

EUnetHTA strengthens role in market access in EU

The thing about small numbers

Marketers working in orphan drugs need to take a narrower, deeper approach to relationship building, and look to medical centres of excellence

Small diseases need big picture communications

An early commitment to communications planning in rare diseases is worth the risk

- PMLiVE

NICE set to extend MabThera recommendation

Says Roche’s drug can be used on NHS to treat two serious forms of vasculitis

Orphan indication? No easy access

Health technology assessment for orphan drugs continues to present challenges for pharmaceutical companies

- PMLiVE

Infographic: Orphan drug market

A visual guide to the orphan drug and rare disease market for pharma

Sanofi reception

Sanofi strikes $700m rare diseases deal

Company's Genzyme division will obtain significant rights to Alnylam’s pipeline of orphan drugs

Interview: Beate Wieseler, IQWIG

Head of the department of drug assessment at the German HTA body on taking a pragmatic approach to comparing medicines

- PMLiVE

US approval for Novo’s Factor XIII drug Tretten

Becomes first recombinant treatment licensed for a rare clotting disorder

- PMLiVE

IMS Health acquires HGS Europe

Founders Graeme and Angela McFarlane bring HGS' market access services to IMS' UK team

- PMLiVE

EMA: more fee reductions for orphan drugs

Greater incentives introduced for larger companies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links